stockrow
Saturday 7 November 2026
Export IBIO’s income statement to Excel — free account
iBio, Inc.
IBIO Healthcare Biotechnology
iBio, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $100,000.00, down 75.0% from fiscal 2025.
- Revenue
- +100.0%
- EPS
- +80.5%
- Free cash flow
- −35.3%
Quarter to June 2026, against a year earlier
0.75
0.02
+2.74%
Follow IBIO
Alert me
iBio, Inc. (IBIO) P/E ratio
iBio, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.8× (April 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 0.0× | — |
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| Dec 2024 | 0.0× | — |
| Jun 2024 | 0.0× | — |
| 31 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.8×
Ten-year median
0.0×
Current reading's percentile
98
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IBIO iBio, Inc. | n/m |
| BMEA Biomea Fusion, Inc. compare | n/m |
| ATHE Alterity Therapeutics Limited - Sponsored ADR compare | n/m |
| MREO Mereo BioPharma Group plc - Sponsored ADR compare | n/m |
| CRBU Caribou Biosciences, Inc. compare | n/m |
| GANX Gain Therapeutics, Inc. compare | n/m |
| HYFT MindWalk Holdings Corp. compare | n/m |
| CNTB Connect Biopharma Holdings Limited Sponsored ADR compare | n/m |
| SER Serina Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)